Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) EBT Margin (2022 - 2025)

Historic EBT Margin for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to 163.66%.

  • ARS Pharmaceuticals' EBT Margin rose 8879800.0% to 163.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 63.59%, marking a year-over-year increase of 22925600.0%. This contributed to the annual value of 9.29% for FY2024, which is 1812259600.0% up from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' EBT Margin is 163.66%, which was up 8879800.0% from 302.95% recorded in Q2 2025.
  • ARS Pharmaceuticals' 5-year EBT Margin high stood at 54.51% for Q4 2024, and its period low was 206030.0% during Q2 2023.
  • Its 4-year average for EBT Margin is 28230.81%, with a median of 1070.74% in 2022.
  • As far as peak fluctuations go, ARS Pharmaceuticals' EBT Margin tumbled by 2000000000bps in 2023, and later skyrocketed by 2000000000bps in 2024.
  • Over the past 4 years, ARS Pharmaceuticals' EBT Margin (Quarter) stood at 3507.94% in 2022, then plummeted by -5773bps to 206030.0% in 2023, then skyrocketed by 100bps to 54.51% in 2024, then tumbled by -400bps to 163.66% in 2025.
  • Its EBT Margin stands at 163.66% for Q3 2025, versus 302.95% for Q2 2025 and 466.29% for Q1 2025.